The U.S. Department of Justice (DOJ) issued its April 2026 rescheduling order, impacting the regulatory landscape for medical cannabis. This order specifically addresses the application of Section 280E of the Internal Revenue Code, a provision that has significantly affected the financial operations of cannabis businesses. While the decision has generated optimism among operators, particularly those in the medical cannabis sector, it also introduces new complexities and uncertainties regarding tax compliance and future business strategies.
Understanding Section 280E and Its Impact
Section 280E of the Internal Revenue Code prohibits businesses involved in trafficking Schedule I or II controlled substances from deducting ordinary business expenses. Under this provision, cannabis operators have historically been limited to deducting only the cost of goods sold under Section 471. This restriction has resulted in effective federal tax rates ranging from 60 to 80 percent, and in some instances higher, for businesses that are otherwise licensed, regulated, and subject to state taxes similar to other industries. According to a report by Cannabis Industry Journal, the collective contested 280E tax liability for the largest publicly traded multi-state operators currently exceeds $1.7 billion.
The statutory basis for this restriction suggests that a reclassification of cannabis to Schedule III could, by its terms, eliminate the application of Section 280E for qualifying entities. This change could lead to an improvement in operator profitability, potentially affecting financial statements and capital allocation.
Scope of the Medical Cannabis Rescheduling Order
The April 23, 2026, DOJ order specifically covers two categories of cannabis products and operators:
- FDA-approved cannabis products.
- Cannabis produced by operators holding a state-issued medical license.
It is important to note that this order does not broadly reschedule all cannabis. Adult-use recreational cannabis operators remain classified under Schedule I. A formal Drug Enforcement Administration (DEA) rulemaking hearing, scheduled for June 29–July 15, 2026, is anticipated to address broader reclassification considerations. Even for qualifying medical operators, the Internal Revenue Service (IRS) has not yet issued formal guidance and continues to litigate existing 280E challenges in Tax Court. A final, legally durable rule encompassing all operators is contingent on the completion of this hearing, a subsequent final rule, a likely 90-day waiting period, and potential legal challenges.
Unresolved Challenges Beyond 280E Relief
While the potential for 280E relief is significant, it does not equate to federal legalization. Several long-standing industry challenges persist:
- Banking Access: Legislative solutions, such as the SAFER Banking Act, remain stalled in the U.S. Congress.
- Interstate Commerce: Restrictions on the movement of cannabis across state lines remain in effect.
- Securities Law: Complications for publicly traded cannabis companies related to securities regulations are not automatically resolved by a scheduling change.
- State/Federal Conflicts: Discrepancies between state and federal cannabis laws continue to exist.
These infrastructure issues continue to influence capital markets and operational strategies within the industry.
Industry Response and Strategic Planning
Operators are currently evaluating several strategic questions in light of the potential 280E changes:
- Will the anticipated tax relief stimulate mergers and acquisitions (M&A) as companies gain additional after-tax capital?
- Will multi-state operators consider restructuring entities to maximize exposure to state medical programs and potentially benefit from early-phase relief?
- Will expansion plans, including new market entries, facility developments, and vertical integrations, which were previously deferred due to 280E’s financial impact, be reactivated?
As of April 22, 2026, state-licensed medical cannabis businesses are no longer subject to Section 280E. The order also encourages the Treasury Department to consider retroactive 280E tax relief for prior years, creating opportunities for businesses to amend returns and file protective claims. Businesses are advised to consult with legal and tax counsel immediately rather than awaiting formal guidance. The deadline to apply through the DEA Diversion portal for expedited DEA registration review is June 26, 2026. While DEA registration may not be mandatory for tax relief, it could offer operational advantages, such as the ability to transport and transact medical cannabis between DEA-registered facilities across state lines and to participate more directly in medical research activities.
For operators navigating this evolving regulatory environment, the potential for 280E relief could significantly alter financial operations. However, the underlying risk environment, including product recall exposure, business interruption vulnerability, and commercial cannabis insurance coverage gaps, remains. Operators who may have previously lacked the capital to address these exposures structurally may now find resources available. Establishing a captive insurance company, for instance, could enable an operator to convert capital into owned, purpose-built coverage, thereby managing risk as a financial asset. Operators should consider the June 26, 2026, DEA registration deadline in consultation with their counsel.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
